ICH = 2 Years after last approval based on study [Regulatives / Guidelines]

posted by Ohlbe – France, 2020-09-01 11:03 (629 d 08:43 ago) – Posting: # 21906
Views: 1,570

Dear Brus,

» 2 Years for ICH? Where did you find that?

In ICH E6 (GCP), § 4.9.5:

Essential documents should be retained until at least 2-years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2-years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period however if required by the applicable regulatory requirements or by an agreement with the sponsor.

Cave: not 2 years after the end of the study, but 2 years after the last approval based on that study.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 11 (0 registered, 11 guests [including 9 identified bots]).
Forum time: Monday 19:46 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5